Omega Medical Imaging, manufactures of Artificial Intelligence Fluoroscopy/Cine (AIF/C) Imaging systems, just announced the Food and Drug Administration 510 (k) clearance of FluoroShield with their 2020 Cardiac Flat Panel Detector. The unique FluoroShield system allows for auto collimation during interventional fluoro or cine cases while maintaining a perspective of surrounding anatomy. The blended image incorporates a lower frequency refresh of the peripheral image area. This combined image (live fluoroscopy or cine of ROI background refreshed at a rate of once or twice per second) increases the quality of information presented during interventional procedures. Brian Fleming, President of Omega Medical Imaging states, "Until now products on the market have only been able to manage radiation to patients and staff. FluoroShield is the only system in the world that provides an actual reduction in dose. The impact of this groundbreaking solution for patients and healthcare providers is substantial. I am very grateful to be a part of a team that pushes the envelope in the development of safer healthcare solutions."

Often, large corporations – which may dominate a market sector like the medical imaging field, which includes computerized tomography (CT), magnetic resonance imaging (MRI) and radiography – are so large they are not able to adapt to new, even disruptive, technologies. Sometimes these are spun off into other companies, as is the case with Harris Corporation and AuthenTec, which developed the fingerprint technology used on Apple phones. Other times, a smaller, nimbler company may emerge that introduces something transformative. Such may be the case with Central Florida's Omega Medical Imaging led by Brian Fleming, which recently received FDA clearance for its FluoroShield system. EW: I want to talk about how you became CEO of Omega, but first, explain the FluoroShield system.